480 ANTIVIRAL THERAPY CAN LEAD TO FIBROSIS REGRESSION IN ANTIHBE-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED IN CLINICAL PRACTICE

Abstract

of patients according to various guidelines and liver histology of these patients. Patients andMethods: 574 HBV patients (353; 61.5% male – median age 46; range 19–78) without clinical or laboratory evidence of cirrhosis were included in the study. Patients were grouped into treatment, follow-up (no treatment) and borderline sub-groups according to age, gender, HBeAG status, serum ALT, HBVDNA levels defined in HBV guidelines published by AASLD, EASL, APASL and WGO. Liver histologies of all patients were evaluated and were grouped as treatment and follow-up groups according to the degree of histologic activity or stage of fibrosis. Results: Of the 574 patients 54(9.4%) had no inflammation, 206(35.9%) had minimal (HAI: 1–4), 141 (24.6%) had mild, 138 (24.1%) had moderate and 35 (6.1%) had severe inflammation. Fibrosis stages were 0 (no fibrosis) in 211 (36.8%), 1–2 in 303 (52.7%) and >2 in 60 (10.45%) patients according to modified Ishak’s method. Treatment was indicated in 157 (27.4%) of the patients according to liver biopsy. Distributions of patients according to treatment guidelines and histopathologic findings (Treatment indicated according to biopsy/treatment indicated according to serum markers) in liver biopsy is shown in table 1. Among the 347 patients with minimal-mild histologic activity 76 (21.9%) had HBVDNA between 2000–20,000 IU/ml and 134 (38.6%) had HBVDNA >20,000 IU/ml.